The roles of lncRNA XIST in cancer chemoresistance

Lee Chia-I; Nadiah Abu; Siti Fathiah Masre

doi:10.55092/exrna20230010

Review

Open Access

The roles of lncRNA XIST in cancer chemoresistance

Lee Chia-I¹Nadiah Abu²^,∗Siti Fathiah Masre¹

¹ Department of Biomedical Science, Center for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Malaysia

² UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Malaysia

* nadiah.abu@ppukm.ukm.edu.my

Volume
Volume 5 Issue 2, 2023
Citation
Chia-I L, Abu N, Masre SF. The roles of lncRNA XIST in cancer chemoresistance. ExRNA 2023(2):0010, https://doi.org/10.55092/exrna20230010.
DOI
10.55092/exrna20230010
Copyright
Copyright2023 by the authors. Published by ELSP.

Abstract

Background and Objective: Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs with a length of more than 200 nucleotides. Multiple studies have shown that lncRNAs are important molecules participating in cellular homeostasis. In fact, it is well known that lncRNAs are often dysregulated in diseases such as cancers. Cancer is a multistep and multifactorial disease. One of the processes that requires further attention is drug or chemoresistance in cancers. LncRNAs are involved in drug resistance as well. Among the different identified lncRNAs, the lncRNA XIST has emerged as a promising biotarget. Therefore, this review is aimed at reviewing the literature to identify the studies reporting on the involvement of XIST in chemoresistance. Key contents and Findings: XIST is involved in the mechanism of various chemotherapeutic drugs involving a lot of cancers. Most of the reported studies suggest a network of XIST-miRNA pathways that are altered in chemoresistant cancers. Conclusion: Based on the available literature, XIST is a promising target for chemoresistance. However, further in-depth studies are needed to validate these findings.

Keywords

XIST; lncRNA; resistance; chemotherapy; cancer

Preview

view pdf

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71(3):209–249. https://doi.org/10.3322/caac.21660.
[2] Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22(47):7512–7523. doi: 10.1038/sj.onc.1206951.
[3] Panni S, Lovering RC, Porras P. Non-coding RNA regulatory networks. Biochim. Biophys. Acta Gene. Regul. Mech. 2020, 1863:194417.
[4] Inamura K. Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. Cells 2017, 6:12.
[5] Churchman LS. Not Just Noise: Genomics and Genetics Bring Long Noncoding RNAs into Focus. Mol. Cell 2017, 65:1–2.
[6] Akhade VS, Pal D, Kanduri C, et al. Long Noncoding RNA: Genome organization and mechanism of action. Adv. Exp. Med. Biol. 2017, 1008:47–74.
[7] Hu G, Niu F, Humburg BA, Liao K, Bendi S, et al. Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget 2018, 9:18648–18663.
[8] Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJ, et al. An atlas of human long non-coding RNAs with accurate 5′ ends. Nature 2017, 543:199–204.
[9] Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 2015, 47(3):199–208.
[10] Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 1991, 349 (6304):38–44.
[11] Cerase A, Pintacuda G, Tattermusch A, Avner P. Xist localization and function: New insights from multiple levels. Genome. Biol. 2015, 16:Article number 166.
[12] Caley DP, Pink RC, Trujillano D, Carter DR. Long noncoding RNAs, chromatin, and development. Sci. World J. 2010, 10:90–102. doi: 10.1100/tsw.2010.7.
[13] Brockdorff N. Polycomb complexes in X chromosome inactivation. Philos. Trans. R. Soc. Lond B Biol. Sci. 2017, 372(1733):20170021. doi: 10.1098/rstb.2017.0021.
[14] Weakley SM, Wang H, Yao Q, Chen C. Expression and Function of a Large Non-coding RNA Gene XIST in Human Cancer. World J. Surg. 2011, 35(8):1751. https://doi.org/10.1007/s00268-010-0951-0.
[15] Sadagopan A, Nasim IT, Li J, Achom M, Zhang CZ, et al. Somatic XIST activation and features of X chromosome inactivation in male human cancers. Cell Syst. 2022, 13(11):932–944.e5. doi: 10.1016/j.cels.2022.10.002.
[16] Strehle M, Guttman M. Xist drives spatial compartmentalization of DNA and protein to orchestrate initiation and maintenance of X inactivation. Curr. Opin. Cell Biol. 2020, 64:139–147.
[17] Dinescu S, Ignat S, Lazar AD, et al. Epitranscriptomic signatures in lncRNAs and their possible roles in cancer. Genes (Basel) 10(1):52.
[18] Zheng W, Li J, Zhou X, Cui L, Wang Y. The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337. Arab. J. Gastroenterol. 2020, 21(3):199–206.
[19] Li P, Wang L, Li P, Hu F, Cao Y, et al. Silencing of long non-coding RNA XIST represses gastric cancer progression through blocking NFκB pathway via inhibiting HNF4A-mediated transcription of EPHA1. Cancer Gene. Ther. 2021, 28:307–320.
[20] Sun N, Zhang G, Liu Y. Long non-coding RNA XIST sponges miR-34a to promotes colon cancer progression via Wnt/β-catenin signaling pathway. Gene 2018, 665:141–148.
[21] Liu PJ, Pan YH, Wang DW, You D. Long non‑coding RNA XIST promotes cell proliferation of pancreatic cancer through miR‑137 and Notch1 pathway. Eur. Rev. Med. Pharmacol. Sci. 2020, 24 (23):12161–12170.
[22] Ning D, Chen J, Du P, Liu Q, Cheng Q, et al. The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer. Liver Int. 2021, 41(8):1933–1944.
[23] Dong Z, Yang J, Zheng F, Zhang Y. et al. The expression of lncRNA XIST in hepatocellular carcinoma cells and its effect on biological function. JBUON 2020, 25(5):2430–2437.
[24] Sun L, Zhang M, Qu H. lncRNA XIST regulates cell proliferation, migration and invasion via regulating miR-30b and RECK in nasopharyngeal carcinoma. Oncol. Lett. 2021, 21(4):256.
[25] Li HL, Han PH, Pan DQ, Chen G, Lu XH, et al. LncRNA XIST regulates cell proliferation, migration and invasion of glioblastoma via regulating MiR-448 and ROCK1. J. Biol. Regul. Homeost. Agents 2020, 34(6): 2049–2058.
[26] Hu B, Shi G, Li Q, Li W, Zhou H. Long noncoding RNA XIST participates in bladder cancer by downregulating p53 via binding to TET1. J. Cell. Biochem. 2019, 120(4):6330–6338.
[27] Zhou K, Yang J, Li X, Chen W. Long non‑coding RNA XIST promotes cell proliferation and migration through targeting miR‑133a in bladder cancer. Exp. Ther. Med. 2019, 18(5):3475–3483.
[28] Jiang Q, Xing W, Cheng J, et al. Knockdown of lncRNA XIST suppresses cell tumorigenicity in human non-small cell lung cancer by regulating miR-142-5p/PAX6 axis. OncoTargets. Ther. 2020, 13: 4919–4929.
[29] Fang H, Yang L, Fan Y, Mo C, Luo L, et al. Upregulation of tissue long noncoding RNA X inactive specific transcript predicts poor postoperative survival in patients with non-small cell lung cancer. Medicine (Baltimore) 2020, 99(50): e21789.
[30] Du YL, Liang Y, Cao Y, Liu L, Li J, et al. LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis. Biochem. Genet. 2021, 59:437–452.
[31] Zhang R, Xia T. Long non-coding RNA XIST regulates PDCD4 expression by interacting with MIR-21-5p and inhibits osteosarcoma cell growth and metastasis. Int. J. Oncol. 2017, 51:1460–1470.
[32] Du Y, Weng XD, Wang L, Liu XH, Zhu HC, et al. LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression. Oncotarget 2017, 8:94358–94370.
[33] Kobayashi R, Miyagawa R, Yamashita H, Morikawa T, Okuma K, et al. Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. Oncol. Lett. 2016, 12:3066–3074.
[34] Liu B, Luo C, Lin H, Ji X, Zhang E, et al. Long Noncoding RNA XIST Acts as a ceRNA of miR-362-5p to Suppress Breast Cancer Progression . Cancer Biother. Radiopharm. 2021, 36(6), 456–466.
[35] Liu K, Gao L, Ma X, Huang JJ, Chen J, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol. Cancer 2020, 19:1–13.
[36] Tang Z, Li C, Kang B, Gao G, Li C, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45(W1):W98–W102. https://doi.org/10.1093/nar/gkx247.
[37] Zhang M, Wang F, Xiang Z, Huang T, Zhou WB. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin. Exp. Pharmacol. Physiol. 2020, 47(8):1464–1472.
[38] Wang C, Li L, Li M, Wang W, Liu Y, et al. Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression. Mol. Med. 2020, 26:114.
[39] Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 2014, 25(18), 2677–2681.
[40] Huang R, Zhu, Zhang Y. XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way. Cancer Cell Int. 2020, 20:436.
[41] Sun J, Pan LM, Chen LB, Wang Y. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle 2017, 16(21):2100–2107.
[42] Sun W, Zu Y, Fu X, Deng Y. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol. Rep. 2017, 38(6), 3347–3354.
[43] Tian LJ, Wu YP, Wang D, Zhou ZH, Xue SB, et al. Upregulation of long noncoding RNA (lncRNA) X-inactive specific transcript (XIST) is associated with cisplatin resistance in non-small cell lung cancer (NSCLC) by downregulating microRNA-144-3p. Med. Sci. Monit. 2019, 25:8095.
[44] Liu TT, Li R, Liu X, Zhou XJ, Huo C, et al. Lncrna xist acts as a microrna-520 sponge to regulate the cisplatin resistance in nsclc cells by mediating bax through cerna network. Int. J. Med. Sci. 2021, 18:419–431.
[45] Xu X, Zhou X, Chen Z, Gao C, Zhao L, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (Albany NY) 2020, 12(6):4711.
[46] Pan B, Lin X, Zhang L, Hong W, Zhang Y. et al. Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance. Melanoma Res. 2019, 29(3):254–262.
[47] Ma SQ, Wang YC, Li Y, Li XY, Yang J, et al. LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p. J. Biol. Regul. Homeost. Agents 2020, 34(6):1993–2001.
[48] Du P, Zhao H, Peng R, Liu Q, Yuan J, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci. Rep. 2017, 37(5):BSR20170696.
[49] Gong M, Wang X, Mu L, Wang Y, Pan J, et al. Steroid receptor coactivator-1 enhances the stemness of glioblastoma by activating long noncoding RNA XIST/miR-152/KLF4 pathway. Cancer Sci. 2021, 112:604–618.
[50] Cheng Z, Luo C, Guo Z. LncRNA-XIST/microRNA-126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma. J. Cell Biochem. 2020, 121(3):2170–2183.
[51] Zhang R, Wang Z, Yu Q, Shen J, He W, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J. Cell. Mol. Med. 2019, 23:3151–3165.
[52] Zeng ZL, Lu JH, Wang Y, Sheng H, Wang YN, et al. The lncRNA XIST/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. Cancer Med. 2021, 10:2423–2441.
[53] Zheng H, Zhang M, Ke X, Deng X, Li D, et al. LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark. 2021, 30(4):395–406.
[54] Xiao Y, Usenko AY, Yosypovych SV. Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget 2017, 8:83171–83182.